Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame.
Identifieur interne : 003041 ( Main/Exploration ); précédent : 003040; suivant : 003042Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame.
Auteurs : Maria P. Rebollo [Royaume-Uni] ; Moses J. BockarieSource :
- Expert review of anti-infective therapy [ 1744-8336 ] ; 2013.
Descripteurs français
- KwdFr :
- Albendazole (administration et posologie), Albendazole (usage thérapeutique), Antihelminthiques (administration et posologie), Antihelminthiques (usage thérapeutique), Chimioprévention (), Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (usage thérapeutique), Filariose lymphatique (), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (transmission), Filariose lymphatique (épidémiologie), Humains, Ivermectine (administration et posologie), Ivermectine (usage thérapeutique), Modèles théoriques, Épidémiosurveillance, Éradication de maladie.
- MESH :
- administration et posologie : Albendazole, Antihelminthiques, Diéthylcarbamazine, Ivermectine.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Antihelminthiques, Diéthylcarbamazine, Filariose lymphatique, Ivermectine.
- épidémiologie : Filariose lymphatique.
- Chimioprévention, Filariose lymphatique, Humains, Modèles théoriques, Épidémiosurveillance, Éradication de maladie.
English descriptors
- KwdEn :
- Albendazole (administration & dosage), Albendazole (therapeutic use), Anthelmintics (administration & dosage), Anthelmintics (therapeutic use), Chemoprevention (methods), Diethylcarbamazine (administration & dosage), Diethylcarbamazine (therapeutic use), Disease Eradication, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (prevention & control), Elephantiasis, Filarial (transmission), Epidemiological Monitoring, Humans, Ivermectin (administration & dosage), Ivermectin (therapeutic use), Models, Theoretical.
- MESH :
- chemical , administration & dosage : Albendazole, Anthelmintics, Diethylcarbamazine, Ivermectin.
- chemical , therapeutic use : Albendazole, Anthelmintics, Diethylcarbamazine, Ivermectin.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial.
- methods : Chemoprevention.
- prevention & control : Elephantiasis, Filarial.
- transmission : Elephantiasis, Filarial.
- Disease Eradication, Epidemiological Monitoring, Humans, Models, Theoretical.
Abstract
Lymphatic filariasis (LF) is an important public health problem endemic in 73 countries, where it is a major cause of acute and chronic morbidity and a significant impediment to socioeconomic development. It is targeted for elimination by 2020, through preventive chemotherapy using albendazole in combination with either ivermectin or diethylcarbamazine citrate. Preventive chemotherapy enables the regular and coordinated administration of safe, single-dose medications delivered through mass drug administration (MDA). Many countries are now scaling down MDA activities after achieving 100% geographic coverage and instituting monitoring and evaluation procedures to establish the impact of several consecutive rounds of MDA and determine if transmission has been interrupted. At the same time, countries yet to initiate MDA for elimination of LF will adopt improved mapping and coverage assessment protocols to accelerate the efforts for achieving global elimination by 2020. This review provides an update on treatment for LF and describes the current global status of the elimination efforts, transmission control processes and strategies for measuring impact and continuing surveillance after MDA has ceased.
DOI: 10.1586/14787210.2013.811841
PubMed: 23879610
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001A03
- to stream PubMed, to step Curation: 001A03
- to stream PubMed, to step Checkpoint: 001A03
- to stream Ncbi, to step Merge: 005B75
- to stream Ncbi, to step Curation: 005B75
- to stream Ncbi, to step Checkpoint: 005B75
- to stream Main, to step Merge: 003046
- to stream Main, to step Curation: 003041
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame.</title><author><name sortKey="Rebollo, Maria P" sort="Rebollo, Maria P" uniqKey="Rebollo M" first="Maria P" last="Rebollo">Maria P. Rebollo</name><affiliation wicri:level="1"><nlm:affiliation>Center for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Center for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA</wicri:regionArea><wicri:noRegion>L3 5QA</wicri:noRegion></affiliation></author><author><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J" last="Bockarie">Moses J. Bockarie</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23879610</idno><idno type="pmid">23879610</idno><idno type="doi">10.1586/14787210.2013.811841</idno><idno type="wicri:Area/PubMed/Corpus">001A03</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A03</idno><idno type="wicri:Area/PubMed/Curation">001A03</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A03</idno><idno type="wicri:Area/PubMed/Checkpoint">001A03</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A03</idno><idno type="wicri:Area/Ncbi/Merge">005B75</idno><idno type="wicri:Area/Ncbi/Curation">005B75</idno><idno type="wicri:Area/Ncbi/Checkpoint">005B75</idno><idno type="wicri:Area/Main/Merge">003046</idno><idno type="wicri:Area/Main/Curation">003041</idno><idno type="wicri:Area/Main/Exploration">003041</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame.</title><author><name sortKey="Rebollo, Maria P" sort="Rebollo, Maria P" uniqKey="Rebollo M" first="Maria P" last="Rebollo">Maria P. Rebollo</name><affiliation wicri:level="1"><nlm:affiliation>Center for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Center for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA</wicri:regionArea><wicri:noRegion>L3 5QA</wicri:noRegion></affiliation></author><author><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J" last="Bockarie">Moses J. Bockarie</name></author></analytic><series><title level="j">Expert review of anti-infective therapy</title><idno type="eISSN">1744-8336</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (administration & dosage)</term><term>Albendazole (therapeutic use)</term><term>Anthelmintics (administration & dosage)</term><term>Anthelmintics (therapeutic use)</term><term>Chemoprevention (methods)</term><term>Diethylcarbamazine (administration & dosage)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Disease Eradication</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Elephantiasis, Filarial (transmission)</term><term>Epidemiological Monitoring</term><term>Humans</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (therapeutic use)</term><term>Models, Theoretical</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Albendazole (administration et posologie)</term><term>Albendazole (usage thérapeutique)</term><term>Antihelminthiques (administration et posologie)</term><term>Antihelminthiques (usage thérapeutique)</term><term>Chimioprévention ()</term><term>Diéthylcarbamazine (administration et posologie)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (transmission)</term><term>Filariose lymphatique (épidémiologie)</term><term>Humains</term><term>Ivermectine (administration et posologie)</term><term>Ivermectine (usage thérapeutique)</term><term>Modèles théoriques</term><term>Épidémiosurveillance</term><term>Éradication de maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chemoprevention</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term><term>Diéthylcarbamazine</term><term>Filariose lymphatique</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Eradication</term><term>Epidemiological Monitoring</term><term>Humans</term><term>Models, Theoretical</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Chimioprévention</term><term>Filariose lymphatique</term><term>Humains</term><term>Modèles théoriques</term><term>Épidémiosurveillance</term><term>Éradication de maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphatic filariasis (LF) is an important public health problem endemic in 73 countries, where it is a major cause of acute and chronic morbidity and a significant impediment to socioeconomic development. It is targeted for elimination by 2020, through preventive chemotherapy using albendazole in combination with either ivermectin or diethylcarbamazine citrate. Preventive chemotherapy enables the regular and coordinated administration of safe, single-dose medications delivered through mass drug administration (MDA). Many countries are now scaling down MDA activities after achieving 100% geographic coverage and instituting monitoring and evaluation procedures to establish the impact of several consecutive rounds of MDA and determine if transmission has been interrupted. At the same time, countries yet to initiate MDA for elimination of LF will adopt improved mapping and coverage assessment protocols to accelerate the efforts for achieving global elimination by 2020. This review provides an update on treatment for LF and describes the current global status of the elimination efforts, transmission control processes and strategies for measuring impact and continuing surveillance after MDA has ceased.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><noCountry><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J" last="Bockarie">Moses J. Bockarie</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Rebollo, Maria P" sort="Rebollo, Maria P" uniqKey="Rebollo M" first="Maria P" last="Rebollo">Maria P. Rebollo</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003041 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003041 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23879610
|texte= Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23879610" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |